Ace Therapeutics has a team of professionals in liver cancer diagnostic technology development to provide technical support and services to our clients worldwide. With our years of practical experience and solid knowledge base, we can provide various assistance to accelerate the development of your diagnostic technology development project.
Liver-related cancers include hepatic hemangioma, hepatic adenoma, hepatocellular carcinoma, bile duct cancer, and other types of cancer. Common diagnostic methods include ultrasound, computed tomography, magnetic resonance imaging (MRI), digital subtraction angiography (DSA), and positron emission computed tomography (PET).
What Can We Do?
The analysis of different liver cancers to obtain more sensitive and accurate biomarkers is the basis for further development of diagnostic techniques for liver cancer. We provide efficient and professional services to screen biomarkers for liver cancer in a comprehensive manner.
- Liver Cancer Biomarkers Discovery
We have extensive experience in the screening of markers. We have perfect solutions for different problems in the screening process and can provide you with systematic research services.
- We have extensive experience in building liver cancer models, both in vitro and in vivo, and will provide targeted liver cancer models according to your needs.
- Based on genomics, proteomics, and metabolomics technologies, we will perform high-throughput screening and analysis of different liver cancers to obtain differential targets.
- Through further screening and validation of the differential targets, we will obtain sensitive and accurate biomarkers for the development of diagnostic technologies.
- Further evaluation and testing of existing liver cancer biomarkers, such as alpha-fetoprotein
- Pathological examination of the liver to assess the characteristic lesions of hepatocellular carcinoma
- Diagnostic Technology Development for Liver Cancer
International guidelines recommend the combined use of positive immunostaining to GPC3, HSP70, or GS for the diagnosis or indication of hepatocellular carcinoma. By using them in combination, 100% specificity and 72% sensitivity are guaranteed. This suggests that high specificity and sensitivity for the diagnosis of hepatocellular carcinoma can be achieved by organic combinations of biomarkers.
Based on the communication and discussion among our scientists in multiple fields, we have established a well-established protocol to organically combine biomarkers associated with hepatocellular carcinoma and to evaluate their diagnostic efficacy. At the same time, we are committed to developing technical services for computer algorithm-based diagnosis of hepatocellular carcinoma to promote further development of hepatocellular carcinoma diagnosis.
Ace Therapeutics brings together experts in the field of liver disease, diagnostics, and computer science to form a dedicated team for liver cancer diagnostic technology development projects. Based on our rich practical experience, we can help your technology development project and provide you with more accurate and scientific-technical support. If you would like to learn more about our services, please feel free to contact us.
Reference
- Piñero, F., et al., Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and treatment response assessment. Cells, 2020. 9(6).
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
